(6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraen-2-one | 149301-78-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraen-2-one
• 英文别名: Aacoch3
• CAS: 149301-78-0
• 化学式: C₂₁H₃₄O
• 分子量: 302.5
• InChiKey: KZEAOOYZYALGAD-ZKWNWVNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  花生四烯酸 、 甲基锂 在 三甲基氯硅烷 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 2.0h， 以62%的产率得到(6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraen-2-one
  参考文献：
  名称：

  紫锥菊和非天然类似物的酮烯烃的合成及其大麻素受体活性。

  摘要：

  尽管紫锥花产品的普及和广泛使用，其功效仍不清楚和有争议。在从紫锥菊中分离出的各种化合物中，仅在淡紫色锥花（E. pallida）中发现的酮烯和酮烯酮是提取物的主要成分。与紫癜链烷酰胺相反，这些化合物尚未合成和研究过免疫刺激作用。我们提出了使用钯催化的交叉偶联反应和对人类大麻素受体的药物合成结果，对酮烯烃的实用和有用的合成方法。所开发的合成路线为酮烯提供了总体良好的收率，并且适用于具有相似的1,4-二烯基序的其他天然产物。在任一受体上均未观察到明显的活性，表明来自E的酮烯。帕利达（Pallida）对通过大麻素系统介导的免疫调节作用不负责任。但是，新合成的非天然类似物在两种大麻素受体上均表现出微摩尔效价。

  DOI：

  10.1002/chem.200801579

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2017037661A1

  公开（公告）日：2017-03-09

  The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's diseasemay be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's diseasesuch as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.

  该发明涉及公式I、公式II和公式III的化合物，或其药用可接受盐，以及其多晶型、溶剂结晶体、对映体、立体异构体和水合物。包括公式I、公式II和公式III化合物的有效量的药物组合物，以及治疗或预防帕金森病的方法可以制成口服、颊下、直肠、局部、经皮、经黏膜、静脉、体内、糖浆或注射剂。这些组合物可用于治疗或管理帕金森病等疾病，如帕金森病、硬皮病、不安腿综合征、高血压和妊娠高血压。
• MODULATORS OF CANNABINOID RECEPTORS
  申请人：UCL Business PLC

  公开号：EP2177503A1

  公开（公告）日：2010-04-21

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group;X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2 CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2-R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X-Y is other than meta-C≡C-(CH2)2CO2H, meta-C≡C-(CH2)2OH, meta-C≡C-(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X-Y is other than meta-C≡C-(CH2)4OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

  本发明涉及一种式 I 的化合物或其药学上可接受的盐、 其中 Z 是 OR1 或 NR1R2，其中 R1 和 R2 各自独立地为 H 或烃基；X 是亚烷基、亚烯基或亚炔基，其中每个亚烷基、亚烯基或亚炔基可任选地被一个或多个选自烷基、COOH、CO2-烷基、烯基、CN、NH2、羟基、卤代、烷氧基、CF3 和硝基的取代基取代； Y 是极性官能团，选自 OH、NO2 CN、COR3、COOR3、NR3R4、CONR3R4、SO3H、SO2-R3、SO2NR3R4 和 CF3，其中 R3 和 R4 各自独立地为 H 或烃基； A 是芳基或杂芳基，每个芳基或杂芳基都可以被任选取代；以及 B 是 (CH2)n，其中 n 是 0、1、2、3、4 或 5； 但条件是 (i) 当 A 是苯基，n 是 0，Z 是 OH 时，X-Y 不是元-C≡C-(CH2)2CO2H、元-C≡C-(CH2)2OH、元-C≡C-(CH2)2CO2Me、元-(CH2)4CO2H、正-CH2CO2H、正-(CH2)2CO2H 和正-(CH2)4CO2H；和 (ii) 当 A 是苯基、n 是 0 和 Z 是 OMe 时，X-Y 不是元-C≡C-(CH2)4OH。 本发明的其他方面涉及将此类化合物用于制备治疗肌肉疾病、胃肠疾病或控制痉挛或震颤的药物。
• Treatment of neurodegenerative conditions
  申请人：Harbige Lawrence S.

  公开号：US20100113595A1

  公开（公告）日：2010-05-06

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.
• Glomerulonephritis Treatment
  申请人：Johansen Berit

  公开号：US20120136066A1

  公开（公告）日：2012-05-31

  A compound of formula (I) R-L-CO—X (I) (wherein R is a C 10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO 2 , said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) or a salt thereof for use in the treatment of glomerulonephritis.
• ALKOXYLATED SORBITAN ESTERS AS CRUDE OIL EMULSION BREAKERS
  申请人：Ecolab USA Inc.

  公开号：US20140213668A1

  公开（公告）日：2014-07-31

  Disclosed herein are alkoxylated sorbitan ester compounds and compositions useful in emulsion breaking applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed herein are methods of using the compounds and compositions as emulsion breakers, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas.